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Results From the UPBEAT (Understanding the
Prognostic Benefits of Exercise and Antidepressant Therapy) Study
Objectives The aim of this study was to assess the efficacy of exercise and antidepressant medication in reducing
depressive symptoms and improving cardiovascular biomarkers in depressed patients with coronary heart
disease.
Background Although there is good evidence that clinical depression is associated with poor prognosis, optimal therapeutic
strategies are currently not well defined.
Methods One hundred one outpatients with coronary heart disease and elevated depressive symptoms underwent assess-
ment of depression, including a psychiatric interview and the Hamilton Rating Scale for Depression. Participants
were randomized to 4 months of aerobic exercise (3 times/week), sertraline (50–200 mg/day), or placebo. Addi-
tional assessments of cardiovascular biomarkers included measures of heart rate variability, endothelial func-
tion, baroreflex sensitivity, inflammation, and platelet function.
Results After 16 weeks, all groups showed improvement on Hamilton Rating Scale for Depression scores. Participants in
both the aerobic exercise (mean 7.5; 95% confidence interval: 9.8 to 5.0) and sertraline (mean 6.1; 95%
confidence interval: 8.4 to 3.9) groups achieved larger reductions in depressive symptoms compared with
those receiving placebo (mean 4.5; 95% confidence interval: 7.6 to 1.5; p  0.034); exercise and sertra-
line were equally effective at reducing depressive symptoms (p  0.607). Exercise and medication tended to
result in greater improvements in heart rate variability compared with placebo (p  0.052); exercise tended to
result in greater improvements in heart rate variability compared with sertraline (p  0.093).
Conclusions Both exercise and sertraline resulted in greater reductions in depressive symptoms compared to placebo in pa-
tients with coronary heart disease. Evidence that active treatments may also improve cardiovascular biomarkers
suggests that they may have a beneficial effect on clinical outcomes as well as on quality of life. (Exercise to
Treat Depression in Individuals With Coronary Heart Disease; NCT00302068) (J Am Coll Cardiol 2012;60:
1053–63) © 2012 by the American College of Cardiology FoundationThe term “cardiovascular vulnerable patients” has been used to
describe patients susceptible to acute coronary events on the
basis of plaque, blood markers, or myocardial characteristics
(1). There now is growing evidence that psychological depres-
ion is associated with increased vulnerability, as it is a
ignificant and independent risk factor for adverse outcomes in
atients with coronary heart disease (CHD) (2–4).
See page 1064
Clinical depression is relatively common in patients with
CHD, with estimates of 15% to 20% of cardiac patients
meeting criteria for major depressive disorder (MDD) and
an additional 20% reporting elevated depressive symptoms
(5–7). A number of studies have reported that the presence of
clinical depression is associated with more than a doubling of
risk for mortality and nonfatal cardiac events (8,9) and that
even subclinical elevations in depressive symptoms are
associated with a worse prognosis in patients with estab-
lished CHD (6,7).
The high prevalence of elevated depressive symptoms in
CHD populations and the increased risk for untoward
cardiac events associated with depression led the American
Heart Association to issue an advisory statement recom-mending that patients with CHD should be screened for
depressive symptoms (4). However, the value of screening
patients for depression has been controversial (10,11), in
part because of a paucity of evidence supporting the value of
treating depression in cardiac patients. Although antide-
pressant medication is widely considered to be the treatment
of choice (12), for a number of patients, medication fails to
adequately relieve depressive symptoms or does so at the
cost of unwanted side effects (13). Moreover, there have
been few randomized clinical trials of established treat-
ments for depression in cardiac patients, and results have
been negative or equivocal (14–18).
There is now good reason to believe that exercise may be
a viable alternative to traditional mental health interventions
in cardiac patients. An increasing number of studies have
shown that exercise may reduce depressive symptoms in
patients with MDD (19) and that exercise may be compa-
rable with established psychological (20) or pharmacological
(21,22) therapies. However, to our knowledge, no random-
ized clinical trial has examined the effects of exercise on
depression in patients with CHD. Because depression also
is related to biomarkers of cardiovascular risk, including
reduced heart rate variability (HRV) (23), low baroreflex
sensitivity (BRS) (24), impaired vascular endothelial func-
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September 18, 2012:1053–63 The UPBEAT Studytion (25), increased platelet activation, and heightened
inflammation (26), as well as health behaviors such as
physical inactivity (27), a secondary goal of the study was to
examine the effects of exercise and antidepressant medica-
tion on these key cardiovascular biomarkers.
Methods
Trial overview. The aims of the UPBEAT (Understand-
ing the Prognostic Benefits of Exercise and Antidepressant
Therapy) study were to: 1) evaluate the effectiveness of
exercise training in reducing depression in patients with
CHD; and 2) examine changes in physiologic biomarkers of
cardiac vulnerability, including measures of HRV, BRS,
vascular endothelial function, inflammation, and platelet
aggregation. Enrollment began in June 2006 and ended in
September 2010. Participants were recruited from physician
referrals, community-based screenings, and mass media
advertisements. After the completion of baseline assess-
ments (see the following discussion), participants were
randomized to exercise, sertraline, or a placebo pill. At the
conclusion of the 4-month treatment period, assessments
were repeated.
UPBEAT was an investigator-initiated trial sponsored by
the National Heart, Lung, and Blood Institute. Sertraline
(Zoloft) and matching placebo pills were supplied by Pfizer,
Inc. (New York, New York), which had no role in the
oversight or design of the study or in the analysis or
interpretation of the data. The trial was approved by the
institutional review board at Duke University Medical
Center, and written informed consent was obtained from all
participants. An independent data and safety monitoring
board oversaw the conduct of the study and reviewed the
safety and efficacy data.
Participants. Eligibility criteria included age 35 years or
older, documented CHD (e.g., prior myocardial infarction,
revascularization procedure, or significant [70% stenosis]
coronary atherosclerosis), and elevated score (7) on the
Beck Depression Inventory (28). Exclusion criteria included
the presence of another primary psychiatric diagnosis, such
as a history of bipolar disorder or psychosis; medical
comorbidities that would preclude participation in the trial
(e.g., significant musculoskeletal disease, cancer); current
psychotherapy or use of antidepressants or other psychotro-
pic medications; history of inability to tolerate or benefit
from sertraline; use of dietary supplements or herbal thera-
pies with purported psychoactive indications; current active
alcohol or drug abuse or dependence; active suicidal intent;
and participation in regular exercise 1 day/week.
Assessment procedures. MEDICAL SCREENING. Before en-
ry into the study, patients underwent physical examinations
y study physicians. Blood pressure was measured using
tandard sphygmomanometry in sitting and standing posi-
ions. Blood specimens were acquired after an overnight fast
or routine electrolytes, pregnancy and liver function tests,
lood count, and thyroid-stimulating hormone assessment.f a patient was found to have
ny significant medical condi-
ion that would contraindicate
afe participation in the study,
e or she was excluded from
articipation.
DEPRESSION ASSESSMENT. All
otential participants were eval-
ated using the Structured Clin-
cal Interview for Depression
29) to determine the presence of
DD and the 17-item Hamil-
on Depression Rating Scale
HAM-D) (30) to assess the se-
erity of depressive symptoms,
oth at baseline and after 4
onths. Assessments were per-
ormed by clinical psychologists
linded to treatment condition.
o ensure patient safety, psy-
hologists blinded to the treat-
ent group administered the HAM-D by telephone weekly
or the first 4 weeks and biweekly for the subsequent 12
eeks to monitor symptom severity and presence of
uicidality.
EXERCISE TESTING. Graded treadmill exercise testing was
onducted before and after treatment to document pa-
ients’ aerobic capacity. Patients exercised to exhaustion
r other standard endpoints under continuous electrocar-
iographic monitoring in which work loads were in-
reased at a rate of 1 metabolic equivalent/min (31).
xpired gases were analyzed continuously using a Parvo
edics True One measurement system (Parvo Medics,
andy, Utah).
HEART RATE VARIABILITY. For our primary cardiovascular
biomarker, an electrocardiogram was recorded for 24 h
using the Lifecard CF, a 3-channel digital compact flash
Holter recorder (DelMar Reynolds, Irvine, California).
During the recording period, patients engaged in their
normal patterns of activity. Electrocardiographic data were
downloaded and edited using the Pathfinder digital ambu-
latory electrocardiographic analyzer (DelMar Reynolds),
and HRV was estimated from the standard deviation of the
normal-to-normal R-R intervals (SDNN).
ENDOTHELIAL FUNCTION ASSESSED BY FLOW-MEDIATED
DILATION (FMD). Brachial artery FMD was assessed after
overnight fasting (32). Longitudinal B-mode ultrasound
images of the brachial artery, 4 to 6 cm proximal to the
antecubital crease, were obtained using an Acuson (Moun-
tain View, California) Aspen ultrasound platform with an
11-MHz linear-array transducer. Images were obtained
after 10 min of supine relaxation and during reactive hyper-
emia, induced after the inflation of a forearm pneumatic
Abbreviations
and Acronyms
TG  beta-
thromboglobulin
BRS  baroreflex
sensitivity
CHD  coronary heart
disease
CI  confidence interval
FMD  flow-mediated
dilation
HAM-D  Hamilton
Depression Rating Scale
HRV  heart rate variability
MDD  major depressive
disorder
PF4  platelet factor 4
SDNN  standard deviation
of the normal-to-normal R-R
intervalsocclusion cuff to suprasystolic pressure (about 200 mmHg) for
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The UPBEAT Study September 18, 2012:1053–635 min. FMD was defined as the maximum percentage change
in arterial diameter relative to resting baseline from 10 to 120 s
after deflation of the occlusion cuff.
BAROREFLEX SENSITIVITY. Beat-by-beat systolic blood
ressure and heart rate were collected using the Finapres
oninvasive blood pressure monitor (model 2300; Ohmeda,
adison, WI). Recordings of beat-by-beat blood pressure
nd R-R interval (derived as 60,000/heart rate) were edited
or artifacts, linearly interpolated, and resampled at a fre-
uency of 4 Hz, to generate an equally spaced time series. A
ast Fourier transformation was then applied to the inter-
olated data after detrending and the application of a
anning filtering window. BRS was estimated from the
agnitude of the transfer function relating R-R interval
scillations to systolic blood pressure oscillations across the
ow-frequency band (0.07–0.1299 Hz).
INFLAMMATION AND PLATELET FUNCTION. Plasma in-
flammatory markers were measured using enzyme-linked
immunosorbent assay. Platelet factor 4 (PF4) and beta-
thromboglobulin (TG) were measured using enzyme-
linked immunosorbent assay using commercially available
kits manufactured by American Diagnostica (Stamford, Con-
necticut) and Diagnostica Stago (Parsippany, New Jersey),
respectively.
Treatment. Participants were randomly assigned to exer-
cise, sertraline, or placebo in a pre-determined 2:2:1 ratio.
Randomization was performed centrally by computer with
conditional randomization (stratified by age [35 to 59 vs.
60 years], CHD status [prior myocardial infarction vs. no
myocardial infarction], and depression severity [HAM-D
score 18 vs. 18]); patients were provided with sealed
envelopes containing their group assignments.
AEROBIC EXERCISE. Patients in the exercise condition at-
ended 3 supervised group aerobic exercise sessions per week
or 16 weeks. On the basis of peak heart rate achieved
uring the initial treadmill test, patients were assigned
raining ranges equivalent to 70% to 85% maximal heart rate
eserve. Each aerobic session consisted of 30 min of walking
r jogging on a treadmill at an intensity that would maintain
eart rate within the assigned training range.
SERTRALINE OR PLACEBO PILL. Participants in the 2 pill
conditions were given the selective serotonin reuptake inhibitor
sertraline or a matching placebo. Medications were taken once
daily; the dosage depended on the clinical response, but usually,
each patient started at 50 mg (1 pill) of drug or placebo and
progressed up to 200 mg (4 pills), contingent on therapeutic
response and the presence of side effects. The treating psychi-
atrist was blinded to pill condition and used supportive mea-
sures to help manage medication side effects.
Outcome assessors were unaware of patients’ treatment
assignments, and only the research pharmacist was aware of
which patients were assigned to sertraline or to placebo.
The primary endpoint was the HAM-D score at the end
of 4 months. Secondary endpoints included remission ofdepression, defined as no Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition, diagnosis of MDD
(33) and a HAM-D score 8 (34), and cardiovascular
biomarkers.
Statistical analysis. The effect of treatment on the primary
and secondary outcomes was evaluated using the general
linear model for continuous variables and unadjusted chi-
square tests for the categorical depression diagnoses and
side-effect outcomes, using SAS version 9.1 (SAS Institute
Inc., Cary, North Carolina). Separate models were esti-
mated for each outcome, with the following predictors: a
treatment group indicator variable, the corresponding pre-
treatment value of the outcome, age, sex, and ethnicity
(Caucasian vs. non-Caucasian). For the HAM-D outcome,
we tested 2 orthogonal contrasts: 1) active treatments (i.e.,
exercise and sertraline) versus placebo and 2) exercise versus
sertraline. In cases in which model residuals did not meet
assumptions, we transformed the outcome and correspond-
ing baseline level of the outcome to ranks, again using the
general linear model. This occurred for SDNN, BRS,
C-reactive protein, interleukin-6, TG, and PF4. This
approach reduces potential bias due to outlying values,
allows the data to better meet model assumptions with
respect to the distribution of residuals, and has been shown
to be equivalent to conventional nonparametric tests (35).
Unless otherwise indicated, treatment effects were analyzed
following the intent-to-treat principle, with post-treatment
missing data managed using the multiple imputation
method available in SAS PROCMI. We estimated that our
sample size would yield about 80% power to detect a 0.66
standard deviation difference between the active treatments
and placebo control and a 0.65 standard deviation difference
between the two active treatments.
Results
Participant flow. Figure 1 displays the flow of participants
through the course of the study. Of the 1,680 participants
who initially inquired about the study, 284 met our initial
inclusion criteria. After screening, 101 participants were
randomized: 37 to the exercise condition, 40 to sertraline,
and 24 to placebo.
Participant characteristics. The sample was generally
middle-aged and older (mean age 63.9 years), primarily
white (73%), and primarily male (68%). The majority of
participants were married, were relatively affluent, and had
at least some college education (Table 1). Forty-seven
participants (47%) met Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, criteria for MDD at
baseline: 46% (n  17) in the exercise group, 50% (n  20)
in the sertraline group, and 42% (n  10) in the placebo
group.
Adherence to exercise and medication. Of the 48 ex-
pected exercise sessions, the median number attended was
45 (94%). Pill adherence was defined as the number of pills
taken divided by the number prescribed. The median
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September 18, 2012:1053–63 The UPBEAT Studyadherence to the pill conditions was 100% (interquartile
range: 97% to 101%), ranging from 83% to 112%. The
median sertraline dose was 50 mg (interquartile range: 50
to 100 mg).
Side effects. Untoward effects of each treatment were
examined by patient ratings on a 36-item symptom check-
list, which was obtained before and after treatment (e.g.,
headaches, dizziness, constipation, muscle pain and sore-
ness). Symptoms were rated on a 5-point, Likert-type scale
ranging from 0 (“never”) to 4 (“almost always”). Relatively
few patients reported a worsening of symptoms after treat-
ment. Among the 36 side effects assessed, only 2 showed a
significant group difference: 20% of patients receiving ser-
traline reported worse post-treatment fatigue compared
with 2.4% in the exercise group and 8.8% in the placebo
group (p  0.025), and 26% reported increased sexual
problems compared with 2.4% in the exercise group and
11.8% in the placebo group (p  0.005).
Changes in aerobic fitness. The exercise group exhibited
greater improvements in peak oxygen consumption and
exercise endurance compared with the sertraline and placebo
groups. Adjusting for pretreatment levels, age, sex, and
ethnicity, the mean post-treatment peak oxygen consump-
tion was greater with exercise (21.3 ml/kg/min; 95% confi-
dence interval [CI]: 20.3 to 22.3 ml/kg/min) compared with
sertraline (18.5 ml/kg/min; 95% CI: 17.5–19.4 ml/kg/min;
p  0.001) and placebo (18.5 ml/kg/min; 95% CI: 17.2–
Figure 1 Participant Flow in the UPBEAT Randomized Clinical T
BDI  Beck Depression Inventory; UPBEAT  Understanding the Prognostic Benefi9.8 ml/kg/min; p  0.002) (Fig. 2A). Participants in the axercise group showed a 9.6% increase in peak oxygen
onsumption compared with sertraline (2.3%) and placebo
2.1%). Similarly, at 16 weeks, treadmill test duration was
onger in the exercise group (8.8 min; 95% CI: 8.3 to 9.4
in) compared with the sertraline (7.1 min; 95% CI: 6.6 to
.7 min; p  0.001) and placebo (7.2 min; 95% CI: 6.5 to
.0; p  0.001) groups (Fig. 2B). The values represented a
9% increase from baseline for exercise and 0.5% and 1%
ecreases for sertraline and placebo, respectively. Body
eight remained essentially constant throughout the study;
here were no group differences in post-treatment body mass
ndex.
hanges in depression. After 16 weeks, all groups showed
mprovements in HAM-D scores. The raw changes in
cores from baseline to 16 weeks among participants with
omplete data were as follows: exercise, 7.5 (95% CI:
9.8 to 5.0); sertraline, 6.1 (95% CI: 8.4 to 3.9);
nd placebo, 4.5 (95% CI: 7.6 to 1.5). The combined
active treatments showed lower HAM-D scores at 16 weeks
compared with placebo (p  0.034), and there was no
difference between exercise and sertraline (p  0.607)
Fig. 3). On the basis of the intention-to-treat analysis, the
AM-D scores after 16 weeks in the exercise group were
.3 points lower compared with the placebo group, while
he average score in the sertraline group was 1.7 points
ower compared with the placebo group.
Among patients diagnosed with MDD initially who were
xercise and Antidepressant Therapy.rial
ts of Evailable for follow-up (n  44), we examined rates of
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The UPBEAT Study September 18, 2012:1053–63remission at 16 weeks, defining remission as the absence of
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, criteria for MDD and a HAM-D score 8
(34). Among the exercise group, 40% (6 of 15) were
remitted, compared with 10% (2 of 20) in the sertraline
group and no participants (0 of 9) in the placebo group
Background Characteristics of SampleTable 1 Background Characteristics of Sam
Variable
Exercise
(n  37)
Age (yrs) 64.7 11.0
Men 65% (24)
Ethnicity
Caucasian 81% (30)
African American 8% (3)
Hispanic 3% (1)
Asian/Pacific Islander 5% (2)
Native American 0
Other 3% (1)
Level of education
Less than high school 8% (3)
High School 11% (4)
Some college 14% (5)
Completed college 11% (4)
Some post-graduate 16% (6)
Complete post-graduate 11% (4)
Annual household income
$45,000 43% (16)
$45,000–$49,999 19% (7)
$50,000–$75,000 14% (5)
$75,000 22% (8)
Married 73% (27)
Employed full-time 32% (12)
Medications
Beta-blockers 92% (34)
ACE inhibitors or ARBs 51% (19)
Aspirin 92% (34)
Other antiplatelet agents 49% (18)
Cholesterol-lowering medications 86% (32)
Nitrates 22% (8)
Prior MI 35% (13)
Prior percutaneous revascularization 68% (25)
Prior CABG 22% (8)
Total cholesterol (mg/dl) 152.8 35.1
LDL cholesterol (mg/dl) 83.5 30.5
HDL cholesterol (mg/dl) 44.0 11.3
Serum triglycerides (mg/dl) 126.4 62.5
Baseline HAM-D score 13.4 5.9
BDI score at baseline 18.5 7.0
DSM diagnosis of major depression 46% (17)
Systolic blood pressure (mm Hg) 130 22
Diastolic blood pressure (mm Hg) 80 11
Peak VO2 (ml/kg/min) 19.5 4.8
Body mass index (kg/m2) 31.0 5.7
Values are mean  SD or % (n). *p values provided at the journal’s r
Kruskal-Wallis or general linear model tests for continuous variables.
ACE  angiotensin-converting enzyme; ARB  angiotensin recepto
grafting; DSM Diagnostic and Statistical Manual of Mental Disorders;
IL  interleukin; LDL  low-density lipoprotein; MI  myocardial infar(chi-square  7.70, 2 degrees of freedom, p  0.021). imong participants who did not meet the criteria for MDD
t baseline, 1 participant in the exercise group and 1
articipant in the placebo group met MDD criteria at 16
eeks. We also examined HAM-D scores among the same
ubgroup of patients initially diagnosed with MDD. Again,
he contrast for active treatments versus placebo was signif-
Sertraline
(n  40)
Placebo
(n  24) p Value*
63.4 10.2 63.5 11.4 0.911
63% (25) 83% (20) 0.189
0.403
70% (28) 67% (16)
23% (9) 13% (3)
0 4% (1)
3% (1) 8% (2)
3% (1) 8% (2)
3% (1) 0
8% (3) 0 0.792
28% (11) 21% (5)
28% (11) 29% (7)
15% (6) 8% (2)
13% (5) 13% (3)
5% (2) 25% (6)
0.276
53% (21) 33% (8)
15% (6) 13% (3)
3% (1) 13% (3)
25% (10) 33% (8)
70% (28) 67% (16) 0.869
25% (10) 38% (9) 0.553
83% (33) 96% (23) 0.201
60% (24) 75% (18) 0.182
83% (33) 96% (23) 0.201
53% (21) 58% (14) 0.761
78% (31) 79% (19) 0.567
40% (16) 29% (7) 0.214
28% (11) 25% (6) 0.647
51% (20) 75% (18) 0.097
33% (13) 29% (7) 0.558
165.8 49.0 158.6 27.9 0.602
92.9 39.7 82.1 15.1 0.743
42.6 10.1 46.6 12.8 0.620
144.2 80.9 157.0 140.0 0.559
14.3 5.8 14.5 5.8 0.764
17.7 9.3 17.5 9.5 0.550
50% (20) 42% (10) 0.549
132 20 126 14 0.604
72 11 71 10 0.670
18.5 6.0 20.1 7.4 0.564
31.5 4.4 30.8 5.1 0.947
are based on Pearson chi-square tests for categorical variables and
r; BDI  Beck Depression Inventory; CABG  coronary artery bypass
 Hamilton Depression Rating Scale; HDL high-density lipoprotein;
O2  oxygen consumption.ple
equest
r blockecant (p  0.042), while the contrast between exercise and
1059JACC Vol. 60, No. 12, 2012 Blumenthal et al.
September 18, 2012:1053–63 The UPBEAT Studysertraline was not (p 0.579). The mean adjusted HAM-D
scores at 16 weeks were 8.8 (95% CI: 6.1 to 11.6) for
exercise, 9.9 (95% CI: 7.4 to 12.3) for sertraline, and 13.6
Figure 2 Aerobic Capacity and Treadmill Time at 16 Weeks Adjus
(A) Aerobic capacity; (B) treadmill time. Contrasts were planned and nonorthogon
The thicker horizontal line represents the median, and the thinner, wider line rep
cise was associated with higher levels of aerobic capacity and longer treadmill tim
Figure 3 HAM-D Scores Adjusted for Age, Sex, Ethnicity, and B
The thicker horizontal line represents the median, and the thinner, wider line rep
Rating Scale (HAM-D) scores were lower for the active treatments (exercise and sertra
(p  0.607).(95% CI: 10.0 to 17.2) for placebo. Among this subgroup,
the changes in HAM-D scores from baseline to 16 weeks
were 9.4 (95% CI: 12.4 to 6.4) for exercise, 8.6
or Age, Sex, Ethnicity, and Baseline Scores of the Outcome
rcise versus sertraline and exercise versus placebo, with Bonferroni correction.
s the mean. Boxes represent 25th and 75th percentiles. After treatment, exer-
pared with either sertraline or placebo (p  0.001). VO2  oxygen consumption.
ine Scores of the Outcome
s the mean. Boxes represent 25th and 75th percentiles. Hamilton Depression
ompared with placebo (p  0.034) but were not different from each otherted f
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8.4 to 0.7) for placebo.
iomarker endpoints. All biomarker endpoint data are
eported in Table 2. For SDNN, our measure of HRV, the
ontrast between the active treatments and placebo ap-
roached significance (p  0.052). At the conclusion of
treatment, the exercise group displayed higher 24-h SDNN
compared with the placebo group. For BRS, the active
treatments combined were not different from placebo (p 
0.515), but exercise was lower compared with sertraline
(p  0.046). For inflammatory biomarkers, patients ran-
omized to exercise had lower levels of interleukin-6 after
reatment compared with those treated with sertraline (p 
.040), but the active treatments combined were not differ-
nt from placebo (p  0.828). There were no treatment
roup differences for FMD, C-reactive protein, TG, or
Biomarkers Before and After TreatmentTable 2 Biomarkers Before and After Treatm
Biomarker
Variable Exercise Only Sertraline
SDNN (ms)*
Before 116 120
After 122 118
Change 6 2
BRS (ms/mm Hg)†
Before 4.8 4.7
After 4.0 5.1
Change 0.8 0.4
FMD (%)
Before 3.5 2.6
After 3.0 4.1
Change 0.5 1.5
CRP (g/ml)
Before 2.5 2.5
After 2.1 2.5
Change 0.4 0
IL-6 (pg/ml)
Before 1.98 1.7
After 1.80 2.1
Change 0.10 0.4
PF4 (IU/ml)
Before 44.1 34.1
After 35.5 34.0
Change 8.6 0.1
TG
Before 137.0 102.5
After 134.3 129.0
Change 2.7 16.5
Values in rows labeled “before” are pre-treatment means. Values in ro
FMD, analyses were performed on imputed rank-transformed values
Pre-treatment and post-treatment means in the table were estima
corresponded to the rank. Pre-treatment values are based on the r
post-treatment ranks. Analysis of treatment effect on FMD was perform
baseline arterial diameter, age, sex, and race. *Analysis based on 9
participants with valid baseline measurements.
ACE  angiotensin-converting enzyme; ARB  angiotensin recepto
grafting; DSM Diagnostic and Statistical Manual of Mental Disorders;
IL  interleukin; LDL  low-density lipoprotein; MI  myocardial infarF4. wiscussion
he results of the UPBEAT trial confirm and extend
vidence for the value of aerobic exercise to treat depression.
articipants with CHD and elevated depressive symptoms
ho were prescribed aerobic exercise 3 times per week for
0 to 45 min per session achieved significantly greater
eductions in depressive symptoms compared with placebo
ontrols; the reduction in depressive symptoms associated
ith exercise was comparable with that observed in patients
eceiving antidepressant medication. Furthermore, exercise
as even more effective in reducing clinical depression in
he subset of patients who were diagnosed with MDD at
tudy entry. Although the sample was small, 40% of patients
ith MDD at the time of randomization were remitted at
he end of 16 weeks of exercise, compared with 10% of those
lacebo
Contrast p Value
All Active Treatment vs.
Placebo
Exercise vs.
Sertraline
23
12 0.052 0.093
11
4.9
4.1 0.515 0.046
0.7
4.4
3.3 0.727 0.131
1.1
2.4
2.5 0.567 0.343
0.1
1.95
1.85 0.828 0.040
0.10
32.0
34.4 0.995 0.712
2.4
03.1
25.0 0.830 0.968
22.1
led “after” are adjusted post-treatment means. With the exception of
ed for baseline level of corresponding outcome, age, sex, and race.
m the ranks, using the nearest value in the original metric that
ks, while post-treatment means were estimated from the adjusted
imputed values in original metric, adjusted for baseline level of FMD,
icipants with valid baseline measurements. †Analysis based on 92
r; BDI  Beck Depression Inventory; CABG  coronary artery bypass
 Hamilton Depression Rating Scale; HDL high-density lipoprotein;
O2  oxygen consumption.ent
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research suggesting that exercise may be a viable alternative to
traditional psychopharmacological treatments of depression.
In an initial study from our group, exercise was shown to
be as effective as antidepressant medication in noncardiac
patients with MDD (21). Because there was no control
condition, however, the benefits could not be attributed to
exercise. In a subsequent study (22), both group exercise and
home-based exercise proved comparable with antidepres-
sant medication and were superior to placebo controls in
non-CHD patients diagnosed with MDD. The present
findings extend these prior reports by demonstrating that
exercise reduces depressive symptoms in patients with stable
CHD. These results may be particularly important in light
of the growing evidence that depression is associated with
increased risk for fatal and nonfatal events in a wide range of
CHD populations (3,4,7,9).
To date, there is limited evidence that traditional treat-
ments are effective for depressed patients with CHD. The
Sertraline Antidepressant Heart Attack Trial reported that
sertraline was no better than placebo in reducing depression
in the entire sample of patients with acute coronary syn-
dromes but was more effective compared with placebo in
reducing depressive symptoms in the subgroup of patients
with more severe MDD (14). The subsequent SADHART-
CHF (Sertraline Against Depression and Heart Disease in
Chronic Heart Failure) trial showed that sertraline per-
formed no better than placebo in patients with heart failure
after 12 weeks of treatment and did not improve clinical
outcomes (15). The CREATE (Canadian Cardiac Ran-
domized Evaluation of Antidepressant and Psychotherapy
Efficacy) trial showed that citalopram was associated with
greater reductions in depressive symptoms compared with
placebo in patients with CHD, but participants also re-
ceived concomitant counseling from nurse clinicians, and
such counseling was found to be more effective than
interpersonal psychotherapy (16). In the ENRICHD (En-
hancing Recovery in Coronary Heart Disease Patients) trial
(18), post–myocardial infarction patients who received cog-
nitive behavior therapy exhibited greater reductions in
HAM-D scores compared with health education controls,
although there were no treatment group differences in
clinical outcomes. Interestingly, secondary analyses of that
trial found that exercise (36) and antidepressant medications
(37) were associated with reduced mortality and nonfatal
myocardial infarction. However, because the patients were
not randomly assigned to exercise or medication, it was
unclear whether either treatment was responsible for the
observed effects. Milani et al. (38) reported that exercise
reduced depression in patients with CHD, but because
participants received concurrent treatments and were not
randomized, reduced depressive symptoms could not be
attributed to exercise. To our knowledge, UPBEAT is the
first randomized clinical trial to show that exercise improves
depression in patients with CHD with MDD or subclinical
depressive symptoms. eIn addition to reduced depression, the 2 active treat-
ments, especially exercise, resulted in increased HRV in
study participants compared with placebo controls. These
findings are consistent with studies of exercise training in
healthy adults (39) and in patients with CHD (40). Prior
studies evaluating antidepressant medications have found
either no effect or possible unfavorable effects on HRV
(14,41).
No improvements were observed in BRS in the treatment
groups compared with placebo controls, although sertraline
resulted in improved BRS compared with exercise. We also
found no evidence for improvements in measures of chronic
inflammation in the active treatments compared with pla-
cebo, although exercise resulted in greater improvements in
interleukin-6 compared with sertraline. Previously, we
found that vascular endothelial function was improved by
exercise (42), but no such benefit was observed in the
present study. In the Sertraline Antidepressant Heart At-
tack Trial, depressed patients with CHD treated with
sertraline had lower levels of TG compared with those
reated with placebo, although there was no difference in
F4. We found no effect of drug therapy on either of these
arkers of platelet activation.
Although there were few side effects associated with
reatment, sertraline was associated with more fatigue and
reater sexual dysfunction relative to placebo and exercise.
exual dysfunction is a common symptom of depression
43) and may be a common side effect of selective serotonin
euptake inhibitors (44), while aerobic exercise has been
ssociated with improved sexual function among men with
rectile dysfunction (45) and with better overall sexual
unction compared with sertraline or placebo pill (46).
tudy limitations. Our relatively small sample size likely
imited our ability to detect small treatment effects for the
iomarkers. Several issues may affect the generalizability of
ur findings. The extent to which UPBEAT patient volun-
eers are representative of the general population of de-
ressed patients with CHD is uncertain. Participants had to
e willing to accept the condition to which they were
andomly assigned, and patients who were not interested in
xercise or taking an antidepressant were unlikely to have
olunteered. We also note that our sample was highly
ducated, with three-quarters of the sample attending at
east some college, which may help explain the high adher-
nce rates observed in our trial.
Another limitation is that we did not examine the
ptimal dose of exercise necessary to improve depression.
ll patients received an exercise prescription of approxi-
ately 90 min of exercise per week (i.e., 30 min 3 times/
eek). Patients were also on relatively low doses of sertra-
ine, with only 30% of patients receiving 100 mg of
ertraline by the end of the trial. Higher doses may have
roduced more favorable effects on the biomarkers but were
ifficult to justify in participants who did not meet criteria
or MDD. Because exercise training was supervised group
xercise, it was confounded with social support, which may
21062 Blumenthal et al. JACC Vol. 60, No. 12, 2012
The UPBEAT Study September 18, 2012:1053–63have augmented the beneficial effects of exercise. However,
our previous work showed that unsupervised, home-based
exercise produced similar reductions in depressive symptoms
compared with supervised exercise (22), and the Depression
Outcomes Study of Exercise established that exercise was
effective in improving depression independent of social
support (47).
Conclusions
The present findings from UPBEAT indicate that depres-
sion can be reduced in cardiac patients. Because of the
paucity of evidence that depression can be successfully
treated, some have questioned the merits of assessing
depression in patients with CHD (10). We believe that the
evidence documenting the association of depression with
poor prognosis and the present findings that depressive
symptoms can be reduced support the recommendation that
routine monitoring of depressive symptoms in patients with
CHD should be performed. Although improvements in
biomarkers do not necessarily translate into improved clin-
ical outcomes (48), our finding that HRV may be reduced in
depressed cardiac patients is encouraging. Although further
research with larger samples is warranted, these findings
provide preliminary evidence that cardiac patients with
elevated depressive symptoms are likely to benefit from the
antidepressant effects of exercise in addition to the well-
documented cardiopulmonary benefits.
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